They can now choose among 4 novel second-generation hormone therapies (the androgen receptor pathway inhibitors [ARPIs] abiraterone, enzalutamide, apalutamide, and darolutamide), 2 chemotherapy ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition ...
In mid-2024, the Company initiated once daily dosing of ORIC-944 in combination with 240 mg QD apalutamide or with 600 mg BID darolutamide, as part of the ongoing Phase 1b trial in patients with ...
Chicago, IL (UroToday.com) Men with low or high-volume metastatic hormone-sensitive prostate cancer who received androgen deprivation therapy (ADT) plus once-daily oral treatment with apalutamide were ...
Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...
(UroToday.com) At the 2021 American Urologic Association (AUA) annual meeting, Dr. Michael Fabrizio discussed real-world utilization of apalutamide and enzalutamide in non-metastatic castrate ...
Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer
The purpose of this study is to determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation therapy (SRT) with enhanced anti-androgen therapy with apalutamide will improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback